Vinva Investment Management Ltd Purchases 12,088 Shares of IQVIA Holdings Inc. $IQV

Vinva Investment Management Ltd raised its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 7.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 173,471 shares of the medical research company’s stock after buying an additional 12,088 shares during the period. IQVIA comprises approximately 0.6% of Vinva Investment Management Ltd’s investment portfolio, making the stock its 29th biggest position. Vinva Investment Management Ltd’s holdings in IQVIA were worth $31,495,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of IQV. Physician Wealth Advisors Inc. lifted its stake in shares of IQVIA by 1,340.0% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock worth $27,000 after acquiring an additional 134 shares during the last quarter. Westside Investment Management Inc. grew its position in IQVIA by 219.6% in the 3rd quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 101 shares during the last quarter. Atlantic Union Bankshares Corp bought a new position in IQVIA in the 3rd quarter valued at $36,000. Root Financial Partners LLC purchased a new stake in IQVIA in the third quarter worth $43,000. Finally, Hantz Financial Services Inc. lifted its position in shares of IQVIA by 92.0% during the third quarter. Hantz Financial Services Inc. now owns 240 shares of the medical research company’s stock worth $46,000 after purchasing an additional 115 shares during the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on IQV shares. BMO Capital Markets set a $250.00 price target on shares of IQVIA in a report on Friday, February 6th. Truist Financial decreased their price objective on shares of IQVIA from $290.00 to $245.00 and set a “buy” rating for the company in a report on Thursday, February 19th. Wall Street Zen upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. JPMorgan Chase & Co. reduced their target price on shares of IQVIA from $255.00 to $225.00 and set an “overweight” rating on the stock in a research report on Friday, February 6th. Finally, Stifel Nicolaus lowered their price target on IQVIA from $273.00 to $220.00 and set a “buy” rating for the company in a report on Friday, February 6th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, IQVIA currently has a consensus rating of “Moderate Buy” and a consensus price target of $231.13.

IQVIA Stock Performance

IQV stock opened at $174.56 on Friday. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $247.04. The business has a 50-day moving average price of $207.22 and a 200 day moving average price of $207.47. The company has a market capitalization of $29.62 billion, a P/E ratio of 22.21, a PEG ratio of 1.68 and a beta of 1.39. The company has a debt-to-equity ratio of 2.09, a current ratio of 0.75 and a quick ratio of 0.75.

IQVIA (NYSE:IQV) last issued its earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.40 by $0.02. The company had revenue of $4.36 billion for the quarter, compared to analysts’ expectations of $4.24 billion. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The firm’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the business earned $3.12 EPS. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, equities research analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.